aTyr Pharma Inc
atyrpharma.comWhat Do They Do?
Develops biologic drug candidates for people with interstitial lung disease and other fibrotic and inflammatory diseases, led by efzofitimod.
10-K for FY2025, filed Mar 5, 2026
How Do They Make Money?
The former Japan license brought upfront and milestone payments tied to development, regulatory, and sales milestones and provided royalties on Japan sales; research and development services bring revenue over time.
10-K for FY2025, filed Mar 5, 2026
$190K
-
10-K for FY2025, filed Mar 5, 2026
$190K ↗
Who Are Their Customers?
Kyorin held a license to develop and commercialize efzofitimod in Japan, while aTyr supplied drug product and supported development; that license has ended.
10-K for FY2025, filed Mar 5, 2026 8-K, filed Jul 31, 2026In January 2020, we entered into a collaboration and license agreement (Kyorin Agreement) with Kyorin for the development and…View ↗
On July 30, 2026, the Company and Kyorin entered into a termination agreement (“Termination Agreement”) whereby the parties mutually agreed…View ↗
Do Revenues Turn Into Profits?
No. It lost $74.1M in FY2025.
10-K for FY2025, filed Mar 5, 2026
−$77.6MView ↗
10-K for FY2025, filed Mar 5, 2026
−$74.1MView ↗
10-K for FY2025, filed Mar 5, 2026
−$62.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$10.3MView ↗
- ▼ −47% (Loss)
- vs −$19.5M in Q2 FY2025
-
Aug 7, 2026
CFO Jill Broadfoot will step down, with Brandon Yaras named as successor
Broadfoot will transition to consulting; Yaras will become CFO.
Sources
8-K, filed Aug 7, 2026
Jill Broadfoot, aTyr’s Chief Financial Officer (CFO), will step down as of September 30, 2026, and transition to serve as a consultant to…View ↗
-
Jul 31, 2026
Kyorin's license ended and Japan rights returned to aTyr
aTyr now holds the right to develop and commercialize efzofitimod globally.
Sources
8-K, filed Jul 31, 2026
On July 30, 2026, the Company and Kyorin entered into a termination agreement (“Termination Agreement”) whereby the parties mutually agreed…View ↗
Pipeline emphasis
The older report discussed an antibody candidate targeting a cell receptor and said aTyr would not use internal resources to start its clinical study; the latest describes preclinical drug candidates derived from other tRNA synthetase domains.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 5, 2026We have also advanced our preclinical pipeline of NRP2 targeting antibody candidates through internal research efforts and academic…View ↗
Who Do They Compete With?
Competes with Boehringer Ingelheim International, Bristol Myers Squibb, Merck, Sanofi-Aventis, GSK, United Therapeutics, F. Hoffmann-La Roche, and Chugai Pharmaceutical
10-K for FY2025, filed Mar 5, 2026There are a number of companies engaged in the clinical development of potential new treatments for ILD, including Boehringer Ingelheim…View ↗
Loading...
